Molecular characteristics of anaplastic astrocytomas and isolation of molecular subgroups of their IDH1 mutant forms using in silico analysis
| Autor: | P. V. Nikitin, A. Yu. Belyaev, M. V. Ryzhov |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
IDH1
idh1 mutation business.industry medicine.medical_treatment anaplastic astrocytoma Treatment outcome Not Otherwise Specified inter-tumor heterogeneity Computational biology Biology medicine.disease IDH2 Targeted therapy nervous system diseases nervous system medicine Molecular Medicine Medicine Personalized medicine business neoplasms Survival analysis Anaplastic astrocytoma |
| Zdroj: | Bûlleten' Sibirskoj Mediciny, Vol 19, Iss 3, Pp 177-187 (2020) |
| ISSN: | 1819-3684 1682-0363 |
| Popis: | Aim. The problem of anaplastic astrocytomas is quite relevant today. The WHO classification distinguishes IDH1 / IDH2 mutant anaplastic astrocytomas, anaplastic astrocytomas without IDH1 / IDH2 mutations, and anaplastic astrocytomas not otherwise specified. The aim of this work was to cluster IDH1 -mutant anaplastic astrocytomas based on their cytogenetic profile to select prognostically significant molecular subgroups, which can have both clinical and fundamental scientific value. Materials and methods . In this work, we performed a cluster analysis of anaplastic astrocytomas according to their cytogenetic profiles based on available genetic databases of tumors and large cohort studies, as well as a comparison of Kaplan – Meyer survival curves for various molecular subgroups of patients. Results. We studied the main genetic features of the inter-tumor heterogeneity of anaplastic astrocytomas and distinguished seven molecular subgroups based on the cytogenetic profile: embryo-like, inflammatory-like, deletion, matrix, cyclin, GATA3 -dependent and tyrosine kinase. Moreover, each of these subgroups has not only distinctive molecular characteristics, but also important clinical features. Conclusion. A detailed study of the molecular properties of anaplastic astrocytomas will not only optimize the process for predicting treatment outcomes, but also create innovative formats for targeted therapy within the framework of the concept of personalized medicine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|